Progyny (NASDAQ:PGNY) Issues FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 2.040-2.100 for the period, compared to the consensus earnings per share estimate of 1.860. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q3 2026 guidance to 0.500-0.520 EPS.

Wall Street Analysts Forecast Growth

PGNY has been the subject of several recent analyst reports. Canaccord Genuity Group raised their target price on shares of Progyny from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Bank of America lifted their price objective on shares of Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Citizens Jmp lifted their target price on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Monday, May 11th. Barclays reissued an “equal weight” rating and issued a $34.00 price objective (up from $27.00) on shares of Progyny in a research note on Tuesday, July 28th. Finally, BTIG Research upped their target price on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Progyny currently has a consensus rating of “Moderate Buy” and an average target price of $33.25.

Progyny Price Performance

Shares of Progyny stock traded down $1.16 during trading on Thursday, hitting $30.21. The company’s stock had a trading volume of 1,863,949 shares, compared to its average volume of 996,015. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 39.23, a price-to-earnings-growth ratio of 2.49 and a beta of 1.01. Progyny has a 52 week low of $16.10 and a 52 week high of $33.06. The stock has a 50-day moving average price of $29.02 and a two-hundred day moving average price of $23.40.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm had revenue of $350.51 million for the quarter, compared to the consensus estimate of $348.63 million. During the same period in the previous year, the business earned $0.19 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities analysts predict that Progyny will post 1.19 EPS for the current fiscal year.

Progyny announced that its Board of Directors has authorized a share buyback program on Tuesday, May 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Insider Activity

In related news, COO Melissa B. Cummings sold 9,578 shares of Progyny stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the sale, the chief operating officer owned 73,371 shares of the company’s stock, valued at approximately $1,834,275. This trade represents a 11.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the transaction, the insider directly owned 59,117 shares in the company, valued at $1,512,212.86. This trade represents a 2.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 36,916 shares of company stock worth $939,875. Company insiders own 9.90% of the company’s stock.

Key Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Second-quarter adjusted earnings were $0.55 per share, well above the reported consensus estimates of $0.33 and $0.51, and up from $0.19 a year earlier. Revenue reached $350.5 million, exceeding the $348.6 million consensus estimate and rising 5.3% year over year. Progyny, Inc. Announces Second Quarter 2026 Results
• Positive Sentiment: Progyny raised or reaffirmed a favorable full-year outlook, forecasting 2026 earnings of $2.04–$2.10 per share, above the $1.86 analyst consensus. Full-year revenue guidance of approximately $1.4 billion was broadly in line with expectations. Progyny Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: The quarter showed improved profitability, with reported net margin of 5.23% and return on equity of 13.34%, potentially supporting the company’s earnings trajectory. Progyny Earnings Report and Conference Call
• Neutral Sentiment: Third-quarter EPS guidance of $0.50–$0.52 exceeded the $0.47 consensus, indicating continued earnings strength.
• Negative Sentiment: Third-quarter revenue guidance of $335 million–$345 million fell below the $350.2 million analyst estimate. The softer near-term top-line outlook may have outweighed the earnings beats, particularly with PGNY trading at a relatively elevated valuation and near its 12-month high. Progyny Q2 CY2026 Results and Stock Reaction

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PGNY. Caitong International Asset Management Co. Ltd purchased a new stake in Progyny in the fourth quarter valued at approximately $25,000. Canada Pension Plan Investment Board purchased a new stake in shares of Progyny during the second quarter worth about $77,000. Quarry LP grew its position in shares of Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after buying an additional 3,427 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Progyny by 203.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock worth $154,000 after acquiring an additional 4,708 shares during the period. Finally, Entropy Technologies LP purchased a new stake in Progyny in the fourth quarter worth $203,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.